Oncology Reimbursement May Be Addressed In Tax Bill This Year
Executive Summary
The American Society of Clinical Oncology hopes that a tax bill this fall will be a vehicle for changing the Medicare Part B payment rate for cancer medicines in 2005
You may also be interested in...
Procrit, Camptosar At Risk Under 2005 Medicare Payment Rates, ASCO Says
Medicare reimbursement rates for 2005 will not cover costs of Johnson & Johnson's Procrit (epoetin) for the majority of oncology practices, according to the American Society of Clinical Oncology
Procrit, Camptosar At Risk Under 2005 Medicare Payment Rates, ASCO Says
Medicare reimbursement rates for 2005 will not cover costs of Johnson & Johnson's Procrit (epoetin) for the majority of oncology practices, according to the American Society of Clinical Oncology
Medicare Cancer Rx Payments Will Be “Disastrous,” Ex-ASCO Head Warns
Oncology drug reimbursement changes mandated by the 2003 Medicare Rx law will cause long term damage to patient care, Memorial Sloan-Kettering Director of Breast Cancer Programs Larry Norton, MD, said June 22 at a Newsweek/Coalition of National Cancer Cooperative Groups panel in Washington, D.C
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: